Sharing of Sublicensing Income. Eidos will pay to Stanford a portion of all Nonroyalty Sublicensing Consideration attributable to the Sublicense of Licensed Patents and Technology, as provided below:
Appears in 4 contracts
Samples: Equity) Agreement, Exclusive (Equity) Agreement (BridgeBio Pharma, Inc.), Exclusive (Equity) Agreement (BridgeBio Pharma LLC)